In recent years, osteoporosis has become a significant issue in developed countries. Romosozumab, which was introduced in 2019, is a relatively novel drug used for osteoporosis treatment. In particular, it can enhance bone mineral density and has new fracture inhibitory effects. Hypocalcemia is a contraindication to romosozumab. The drug should also be administered with caution in patients at high risk of cardiovascular disorders. To maximize its effect, it is better to use romosozumab before starting other osteoporosis medications. Currently, there are no clinical reports on the ability of romosozumab to promote fracture healing. With the use of this drug in combination with others, we can treat as many patients with osteoporosis as possible. This article is based on our study first reported in the Journal of Tokyo Women's Medical University (in Japanese), 2024; 94 (4):71-5.
Tominaga et al. (Sun,) studied this question.